Oral Factor Xa inhibitors

Dabi-SNAP compares switching to dabigatran against continuing the currently prescribed oral FXa inhibitor. Oral FXa inhibitors share dabigatran's main clinical indications but target only Factor Xa. Population-level observational evidence suggested lower invasive S. aureus disease incidence among dabigatran users than oral FXa inhibitor users. The article states that oral FXa inhibitors have no demonstrated direct effect on S. aureus coagulase or staphylothrombin virulence mechanisms.